Dear All:I've just learned of a funding call from Wellcome Leap entitled "Focused antibiotics." The thesis of the call is that the resistance arises (at least in part) when the gut microbiome is exposed incidentally to an antibiotic intended for an infection elsewhere in body (e.g., the lungs).So, this project seeks to support development of technologies that would spare the gut, focus the delivery of the antibiotic to the site of infection, and (thereby) reduce the rate of emergence of resistance. Here are the data you need:The call itself: webpage, detailed program announcement, FAQCall summary: Broadly, it seeks two types of projects (I am paraphrasing a bit):Development of formulations of existing antibiotics that (i) target an antibiotic to the site of infection while both (ii) not impacting the gut microbiome and (iii) maintaining or improving efficacy in pre-clinical in vitro and animal models.Development of methods to identify specific antibiotic-induced human gut microbiome changes that predict the development of subsequent resistant bacterial infection with >80% accuracy.Who is eligible? Pretty much anyone: "... universities and research institutions; small, medium, and large companies (including venture-backed); and government or non-profit research organizations ... from any legal entity, based in any legal jurisdiction, including academic, non-profit, for-profit, and regulatory/professional...